HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
BCAX
Bicara Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.35B
Market Cap
$1.35B
Enterprise Val
$807.7M
P/E Ratio
-8.56
P/B Ratio
2.62
Trailing PEG (1Y)
-0.23
As Of
Jun 8, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$514.0M
Return on Equity-35.89%
Return on Assets-33.78%
Current Ratio13.85
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Mar 31, 2026
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$47.5M
SG&A$12.7M
Operating Expenses$60.2M
Operating Income-$60.2M
Interest Expense$0.00
Tax Expense$52.0K
Net Income-$56.2M
EPS (Basic)$-0.93
EPS (Diluted)$-0.93
EBIT-$56.2M
EBITDA-$55.8M
Consolidated Income-$56.2M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$323.5M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$544.9M
LT Investments$0.00
Property, Plant & Equipment$1.8M
Intangibles$0.00
Non-Current Assets$8.7M
Total Assets$553.6M
Accounts Payable$7.4M
Current Debt$1.1M
Current Liabilities$39.3M
LT Debt$301.0K
Non-Current Liabilities$301.0K
Total Liabilities$39.6M
Total Debt$1.4M
Retained Earnings-$415.2M
Shareholder Equity$514.0M
Shares Outstanding65,467,187

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$37.5M
Investing Cash Flow$100.9M
Financing Cash Flow$163.3M
CapEx-$60.0K
Free Cash Flow-$37.6M
Depreciation & Amort.$317.0K
Stock-Based Comp$5.9M
Acquisitions / Disposals$0.00
Investment Activity$101.0M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$163.3M
Dividends Paid$0.00
Net Change in Cash$226.8M
Data cached · Meta live · Daily live · Statements live · TTL 24h